CNSP CNS Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1729427 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY-102.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-124.8%
ROA-106.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets13.1%
Debt / equity0.00x
Current ratio7.65x
Interest coverage-1,031.22x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $9.77M | $9.29M | $14.10M | $9.30M | $9.81M |
| SG&A expense | $6.21M | $5.61M | $4.77M | $5.97M | $4.68M |
| Operating income | -$15.99M | -$14.90M | -$18.87M | -$15.27M | -$14.49M |
| Interest expense | $15,230 | $16,120 | $13,805 | $7,027 | $9,285 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$15.85M | -$14.86M | -$18.85M | -$15.27M | -$14.50M |
| EBITDA | -$15.98M | -$14.90M | -$18.86M | -$15.26M | -$14.47M |
| EPS (basic) | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 |
| EPS (diluted) | -35.75 | -466.89 | -12,509.11 | -11.22 | -16.50 |
| Weighted avg. shares (diluted) | 443,369 | 31,823 | 1,507 | 1.36M | 878,443 |
| Balance sheet | |||||
| Cash & equivalents | $7.20M | $6.46M | $548,721 | $10.06M | $5.00M |
| Current assets | $8.10M | $8.66M | $1.59M | $12.56M | $7.48M |
| PP&E, net | $18,000 | $6,005 | $4,933 | $5,664 | $16,109 |
| Total assets | $8.62M | $8.70M | $1.70M | $13.05M | $8.76M |
| Current liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.59M |
| Total liabilities | $4.10M | $2.52M | $6.13M | $4.92M | $2.59M |
| Shareholders' equity | $4.52M | $6.18M | -$4.43M | $8.13M | $6.16M |
| Shares outstanding | 632,516 | 117,796 | 2,486 | 1.62M | 949,052 |
| Cash flow statement | |||||
| Operating cash flow | -$13.81M | -$17.11M | -$14.14M | -$10.56M | -$13.54M |
| Capital expenditure | $18,175 | $4,188 | $3,901 | $4,422 | $5,748 |
| Free cash flow | -$13.83M | -$17.12M | -$14.14M | -$10.56M | -$13.54M |
| Investing cash flow | -$18,175 | -$4,188 | -$3,901 | -$4,422 | -$5,748 |
| Financing cash flow | $14.57M | $23.03M | $4.64M | $15.61M | $4.51M |
| Depreciation & amortization | $3,918 | $3,306 | $4,134 | $11,756 | $13,070 |
| Stock-based compensation | $187,728 | $838,957 | $1.01M | $1.20M | $1.72M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.